In Vivo siRNA Delivery to Immunosuppressive Liver Macrophages by [alpha]-Mannosyl-Functionalized Cationic Nanohydrogel Particles

• Published in: Cells (Basel, Switzerland) Vol. 9; no. 8; p. 1
• Main Authors: Kaps, Leonard, Leber, Nadine, Klefenz, Adrian, Choteschovsky, Niklas, Zentel, Rudolf, Nuhn, Lutz, Schuppan, Detlef
• Format: Journal Article
• Language: English
• Published: MDPI AG 01.08.2020
• Subjects: Methods; RNA sequencing; Germany
• DOI: 10.3390/cells9081905
• ISSN: 2073-4409

Macrophages are the front soldiers of the innate immune system and are vital for immune defense, tumor surveillance, and tissue homeostasis. In chronic diseases, including cancer and liver fibrosis, macrophages can be forced into an immunosuppressive and profibrotic M2 phenotype. M2-type macrophages overexpress the mannose receptor CD206. Targeting these cells via CD206 and macrophage repolarization towards an immune stimulating and antifibrotic M1 phenotype through RNA interference represents an appealing therapeutic approach. We designed nanohydrogel particles equipped with mannose residues on the surface (ManNP) that delivered siRNA more efficiently to M2 polarized macrophages compared to their untargeted counterparts (NonNP) in vitro. The ManNP were then assessed for their in vivo targeting potential in mice with experimental liver fibrosis that is characterized by increased profibrotic (and immunosuppressive) M2-type macrophages. Double-labelled siRNA-loaded ManNP carrying two different near infrared labels for siRNA and ManNP showed good biocompatibility and robust uptake in fibrotic livers as assessed by in vivo near infrared imaging. siRNA-ManNP were highly colocalized with [CD206.sup.+] M2-type macrophages on a cellular level, while untargeted NP (NonNP) showed little colocalization and were non-specifically taken up by other liver cells. ManNP did not induce hepatic inflammation or kidney dysfunction, as demonstrated by serological analysis. In conclusion, [alpha]-mannosyl-functionalized ManNP direct NP towards M2-type macrophages in diseased livers and prevent unspecific uptake in non-target cells. ManNP are promising vehicles for siRNA and other drugs for immunomodulatory treatment of liver fibrosis and liver cancer.